Fig. 2From: Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trialDM stratified by CAB in designated subgroups. A DM for exemestane arm. Interaction (randomization vs CAB) P < 0.001. B DM for the sequential arm. C Patients received endocrine therapy alone subgroup. D Patients with lymph node-positive received endocrine therapy aloneBack to article page